Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAG-01 intravesical therapy in intermediate/high-risk NMIBC
CTR20263149Phase 2Active
- Sponsor
- Ractigen Therapeutics
- Start
- Aug 2026
- Modality
- Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of RAG-01 in non-muscle-invasive bladder cancer (NMIBC), sponsored by Ractigen Therapeutics. Started Aug 2026; status: active.
02
Drugs
RAG-01
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on CTR20263149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263149.